Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

HESTER BIOSCIENCES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 HESTER BIOSCIENCES   ACTAVIS
EQUITY SHARE DATA
    HESTER BIOSCIENCES
Mar-23
ACTAVIS
Dec-18
HESTER BIOSCIENCES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs2,85216,136-   
Low Rs1,41610,824-   
Sales per share (Unadj.) Rs312.73,958.1-  
Earnings per share (Unadj.) Rs32.9-1,274.9-  
Cash flow per share (Unadj.) Rs57.3417.1-  
Dividends per share (Unadj.) Rs8.000-  
Avg Dividend yield %0.40-  
Book value per share (Unadj.) Rs328.716,325.5-  
Shares outstanding (eoy) m8.51332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x6.83.4 200.3%   
Avg P/E ratio x64.7-10.6 -612.4%  
P/CF ratio (eoy) x37.332.3 115.3%  
Price / Book Value ratio x6.50.8 785.9%  
Dividend payout %24.30-   
Avg Mkt Cap Rs m18,1524,483,446 0.4%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m5600-   
Avg. sales/employee Rs Th077,898.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,091.0-  
INCOME DATA
Net Sales Rs m2,6611,316,478 0.2%  
Other income Rs m15425,175 0.6%   
Total revenues Rs m2,8141,341,653 0.2%   
Gross profit Rs m54834,498 1.6%  
Depreciation Rs m207562,766 0.0%   
Interest Rs m9375,968 0.1%   
Profit before tax Rs m402-579,060 -0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,684 0.0%   
Tax Rs m121-7,338 -1.7%   
Profit after tax Rs m280-424,038 -0.1%  
Gross profit margin %20.62.6 786.1%  
Effective tax rate %30.21.3 2,381.6%   
Net profit margin %10.5-32.2 -32.7%  
BALANCE SHEET DATA
Current assets Rs m2,276539,950 0.4%   
Current liabilities Rs m1,487477,658 0.3%   
Net working cap to sales %29.74.7 626.6%  
Current ratio x1.51.1 135.4%  
Inventory Days Days4720 241.0%  
Debtors Days Days10966 164.7%  
Net fixed assets Rs m4,424149,018 3.0%   
Share capital Rs m850-   
"Free" reserves Rs m2,7120-   
Net worth Rs m2,7975,429,856 0.1%   
Long term debt Rs m1,8491,912,049 0.1%   
Total assets Rs m6,7008,488,101 0.1%  
Interest coverage x5.3-6.6 -80.2%   
Debt to equity ratio x0.70.4 187.7%  
Sales to assets ratio x0.40.2 256.1%   
Return on assets %5.6-4.1 -136.0%  
Return on equity %10.0-7.8 -128.3%  
Return on capital %10.6-4.8 -220.0%  
Exports to sales %11.60-   
Imports to sales %00-   
Net fx Rs m2700-   
CASH FLOW
From Operations Rs m236470,328 0.1%  
From Investments Rs m-770258,384 -0.3%  
From Financial Activity Rs m418-807,224 -0.1%  
Net Cashflow Rs m-116-78,120 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.39 Rs / USD

Compare HESTER BIOSCIENCES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare HESTER BIOSCIENCES With: ORCHID PHARMA  J.B.CHEMICALS  CORAL LAB.  LUPIN  RPG LIFE SCIENCES  



Today's Market

Gland Pharma Receives USFDA Approval | Maruti Suzuki Crosses Rs 8 Trillion Mark | Top Buzzing Stocks Today Gland Pharma Receives USFDA Approval | Maruti Suzuki Crosses Rs 8 Trillion Mark | Top Buzzing Stocks Today(Pre-Open)

Indian share markets continued the momentum as the session progressed and ended on firm footing.